Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Department of Neurology, Tianjin Key Laboratory of Cerebrovascular and of Neurodegenerative Diseases, Tianjin Dementia Institute, Tianjin Huanhu Hospital, Tianjin, China.
Eur J Neurol. 2023 Dec;30(12):3711-3721. doi: 10.1111/ene.16002. Epub 2023 Aug 7.
White matter hyperintensities (WMHs) are associated with cognitive deficits and worse clinical outcomes in dementia, but rare studies have been carried out of cognitive impairment in Lewy body disease (CI-LB) patients. The objective was to investigate the associations between WMHs and clinical manifestations in patients with CI-LB.
In this retrospective multicentre cohort study, 929 patients (486 with dementia with Lewy bodies [DLB], 262 with Parkinson's disease dementia [PDD], 74 with mild cognitive impairment [MCI] with Lewy bodies [MCI-LB] and 107 with Parkinson's disease with MCI [PD-MCI]) were analysed from 22 memory clinics between January 2018 and June 2022. Demographic and clinical data were collected by reviewing medical records. WMHs were semi-quantified according to the Fazekas method. Associations between WMHs and clinical manifestations were investigated by multivariate linear or logistic regression models.
Dementia with Lewy bodies patients had the highest Fazekas scores compared with PDD, MCI-LB and PD-MCI. Multivariable regressions showed the Fazekas score was positively associated with the scores of Unified Parkinson's Disease Rating Scale Part III (p = 0.001), Hoehn-Yahn stage (p = 0.004) and total Neuropsychiatric Inventory (p = 0.001) in MCI-LB and PD-MCI patients. In patients with DLB and PDD, Fazekas scores were associated with the absence of rapid eye movement sleep behaviour disorder (p = 0.041) and scores of Unified Parkinson's Disease Rating Scale Part III (p < 0.001), Hoehn-Yahn stage (p < 0.001) and the Montreal Cognitive Assessment (p = 0.014).
White matter hyperintensity burden of DLB was higher than for PDD, MCI-LB and PD-MCI. The greater WMH burden was significantly associated with poorer cognitive performance, worse motor function and more severe neuropsychiatric symptoms in CI-LB.
脑白质高信号(WMHs)与痴呆患者的认知功能减退和临床结局恶化有关,但针对路易体病(LB)患者认知障碍(CI-LB)的研究很少。本研究旨在探讨 CI-LB 患者 WMHs 与临床表现之间的关系。
本回顾性多中心队列研究纳入了 2018 年 1 月至 2022 年 6 月期间来自 22 个记忆诊所的 929 名患者(929 名患者,486 名痴呆伴路易体病(DLB),262 名帕金森病痴呆(PDD),74 名轻度认知障碍伴路易体(MCI-LB),107 名帕金森病伴 MCI(PD-MCI))。通过查阅病历收集人口统计学和临床数据。WMHs 采用 Fazekas 法进行半定量分析。通过多变量线性或逻辑回归模型研究 WMHs 与临床表现之间的关系。
与 PDD、MCI-LB 和 PD-MCI 相比,DLB 患者的 Fazekas 评分最高。多变量回归显示,在 MCI-LB 和 PD-MCI 患者中,Fazekas 评分与统一帕金森病评定量表第三部分(UPDRS-III)评分(p=0.001)、Hoehn-Yahn 分期(p=0.004)和神经精神问卷总分(NPI)(p=0.001)呈正相关。在 DLB 和 PDD 患者中,Fazekas 评分与快动眼睡眠行为障碍(RBD)缺失(p=0.041)、UPDRS-III 评分(p<0.001)、Hoehn-Yahn 分期(p<0.001)和蒙特利尔认知评估(MoCA)评分(p=0.014)相关。
DLB 的 WMH 负荷高于 PDD、MCI-LB 和 PD-MCI。WMHs 负担的增加与 CI-LB 患者认知功能下降、运动功能恶化和更严重的神经精神症状显著相关。